TI:Serum HBV2DNA level can predict treatment effectiveness in patients with chronic hepatitis B using interferon2α22a 　
AU:ZHAO Hong, WANG Guiqiang,HAN Zhonghou , YU Min , WANG Yuhua , SUN Xiewen ,YU Yanyan , WANG Qinhuan , SI Chongwen , TIAN Gengshan , HAN Xiangyun
AD:The Department of Infectious Diseases , The First Teaching Hospital of Beijing University , Beijing 100034 , China Corresponding author : WANG Gui2qiang , E2mail : wanggq @hotmail1com
【Abstract】　Objective 　To evaluate the correlation between the efficacy of interferon2α2
2a and the kinetics of viral load in serum1 Methods 　The authors conducted a trial including 58 patients with chronic hepatitis B1Patients were treated with interferon2α22a three times a week for 6 months1 Viral kinetics were assessed by serialquantitive measurements of HBV2DNA1 Results 　A significant decline of serum HBV2DNA was seen afterinterferon2α22a administration for 1 month ,the decreases were (2150 ±0144) log10 , (1162 ±1112) log10 and (1105±1135) log10 for complete responders , partial responders and no2responders , respectively1 After 1 month of treatment , HBV2DNA level was (3199 ±0191) log10 for complete responders versus (5163 ±1131) log10 for partial responders , and ( 6169 ±1142) log10 for no2responders ( P < 0105) 1 Multivariate analysis suggested that undetectable serum HBV2DNA after 1 month of interferon2α22a treatment was associated with better efficacy ; higher baseline ALT orPand no family history were also correlated with better treatment outcomes1 Conclusion 　Kinetics of HBV2DNA level under interferon2α2 2a treatment are highly predictive of therapeutic response1
【Key words】　Hepatitis B , chronic ; 　DNA; 　Interferon2alpha